Anúncio
Anúncio

BCRX

BCRX logo

BioCryst Pharmaceuticals Inc

7.62
USD
Patrocinado
-0.30
-3.85%
08 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

7.58

-0.03
-0.39%

Relatórios de Lucros BCRX

Rácio de surpresa positiva

BCRX separação 22 de 40 últimas estimativas.

55%

Próximo Relatório

Data do Próximo Relatório
23 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$153.28M
/
$0.03
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-3.84%
/
-50.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+16.53%
/
-123.08%

BioCryst Pharmaceuticals Inc earnings per share and revenue

On 03 de nov. de 2025, BCRX reported earnings of 0.06 USD per share (EPS) for Q3 25, beating the estimate of 0.03 USD, resulting in a 67.13% surprise. Revenue reached 159.40 milhão, compared to an expected 166.23 milhão, with a -4.11% difference. The market reacted with a -6.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analistas forecast an EPS of 0.03 USD, with revenue projected to reach 153.28 milhão USD, implying an diminuir of -50.00% EPS, and diminuir of -3.84% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, BioCryst Pharmaceuticals Inc reported EPS of $0.06, beating estimates by 67.13%, and revenue of $159.40M, -4.11% below expectations.
The stock price moved down -6.28%, changed from $7.32 before the earnings release to $6.86 the day after.
The next earning report is scheduled for 23 de fev. de 2026.
Based on 13 analistas, BioCryst Pharmaceuticals Inc is expected to report EPS of $0.03 and revenue of $153.28M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio